Gemcitabine-Docetaxel May Be a Feasible Alternative to BCG f

Investigators report their early clinical experience using intravesical sequential gemcitabine-docetaxel as first-line therapy for high-risk nonmuscle-invasive bladder cancer. Intravesical sequential gemcitabine-docetaxel may be a feasible alternative to BCG for high-risk nonmuscle-invasive bladder cancer (NMIBC).

Related Keywords

Winston Salem , North Carolina , United States , Washington , Wake Forest University , Justin Manuel Refugia , Vignesht Packiam , Wake Forest University School Of Medicine , University Of Iowa , Society Of Urologic Oncology , Urologic Oncology , Wake Forest University School , Cancers Symposium , Iowa City ,